
|Videos|June 9, 2020
SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?
Author(s)Grant M. Gallagher
Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.
Advertisement
Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
Vaccines as a Secondary Strategy in the Fight Against Antimicrobial Resistance
2
Antibiotic Shows Promise in Treating Gram-Positive Pneumonia, Including in High-Risk Patients
3
As NDM-CRE Infections Rise Significantly, Diagnostic Access Emerges as Weak Link
4
Emerging Diagnostic Tools and Mycobacterial Challenges in Skin and Soft Tissue Infections
5